4.8 Article

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

期刊

NATURE
卷 481, 期 7380, 页码 157-163

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nature10725

关键词

-

资金

  1. St Jude Children's Research Hospital
  2. The Genome Institute and Siteman Cancer Center at Washington University in St Louis
  3. The St Jude Children's Research Hospital-Washington University Pediatric Cancer
  4. ALSAC of St JudeChildren's Research Hospital
  5. Cancer Center [P30CA021765]
  6. Washington University in St Louis [NIHU 01GM92666-PAAR4Kids]
  7. National Human Genome Research Institute (NHGRI) [U54 HG003079]
  8. NCI [CA98543, CA98413, CA114766]
  9. Alex's Lemonade Stand
  10. St. Baldrick's Foundation
  11. Haematology Society of Australasia
  12. New Zealand New Investigator Scholarship

向作者/读者索取更多资源

Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy of unknown genetic basis. We performed whole-genome sequencing of 12 ETP ALL cases and assessed the frequency of the identified somatic mutations in 94 T-cell acute lymphoblastic leukaemia cases. ETP ALL was characterized by activating mutations in genes regulating cytokine receptor and RAS signalling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF), inactivating lesions disrupting haematopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1 and EP300) and histone-modifying genes (48%; EZH2, EED, SUZ12, SETD2 and EP300). We also identified new targets of recurrent mutation including DNM2, ECT2L and RELN. The mutational spectrum is similar to myeloid tumours, and moreover, the global transcriptional profile of ETP ALL was similar to that of normal and myeloid leukaemia haematopoietic stem cells. These findings suggest that addition of myeloid-directed therapies might improve the poor outcome of ETP ALL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据